亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

B7H3 CAR-T therapy in relation to tumor growth in skin tumor.

作者
Gang Hu,Yunsheng Liang,Guangchao Li,Wen Yuan Ding,Min Luo
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16_suppl): e21502-e21502 被引量:2
标识
DOI:10.1200/jco.2022.40.16_suppl.e21502
摘要

e21502 Background: Exciting progress has been recently witnessed on the development of chimeric antigen receipt T cell (CAR-T) therapy for hematopoietic malignancies. The biological principles of CAR-T therapy are applicable to solid tumors but very little success has been achieved due to various challenges intrinsic to solid tumors. The development of new solid tumor targets is particularly important. CD276 (B7H3) is one of the most promising therapeutic targets for solid tumors and has been extensively tested in preclinical trials. However, no clinical trials have been reported on its efficacy and safety. In this study, we report a case of relapsed basal cell carcinoma (BCC) patient treated with B7H3 CAR-T cells through direct intra-tumor injection. Trial registration number: ChiCTR2100044386. Methods: We have generated a 2nd generation of B7H3 CAR-T, the extracellular scFv was derived from a humanized B7H3 monoclonal antibody, which was generated by hybridoma technology. Autologous CAR-T cells were manufactured in a cGMP facility. CAR-T cells were given by three dose-escalated intra-tumor injections without lymphodepletion conditioning. Results: A 65-year-old man was initially diagnosed with multiple BCC, the disease relapsed and spread to all over the body. Immunohistochemical staining of the tumor tissue showed positive for B7H3 (80%, ++̃+++). The patient received autologous anti-B7H3 CAR-T therapy cells through intra-tumor injection three times with dose escalation on day 1, day 14 and day 62. There were two different tumor sites that were treated in this patient (site 1 for abdominal tumor 1.8 cm × 0.6 cm; site 2 for forehead tumor 6 cm × 6 cm). For the adverse events, the patient’s AST/ALT levels slightly increased about two fold after the first infusion. However, we did not observe increases of AST/ALT levels after the second and third infusion, even with much higher dose. After three infusions, the volume of original lesion in the abdomen decreased 40% (1.8cm × 0.6cm to 1.3cm × 0.5cm), shrinking from bulging to flat. The large lesion in the forehead became dry from original ulcer and bleeding. We further performed surgery to remove the remained tumor in the abdomen after the third infusion. IHC analysis demonstrated that the percentage of B7H3 positive cells decreased from 80% to about 40%, and the intensity also decreased from ++̃+++ to +. Meanwhile, CD3 T cells increased in the tumor site, but failed to efficiently infiltrate into neighboring tumor areas, which was marked by high level of TGF-β. Conclusions: In this case, we reported for the first time that a patient with skin tumor achieved a partial response after receiving repeated intra-tumor injections of anti-B7H3 CAR-T cells. This study demonstrated that B7-H3 CAR-T cell therapy is a safe and promising treatment for relapsed skin tumor. Combination with other strategies to improve CAR-T cell infiltration in the tumor site may help to further improve the clinical response. Clinical trial information: ChiCTR2100044386.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
温暖山晴完成签到,获得积分10
2秒前
ket的应助被YUYUYU采纳,获得10
9秒前
zzmine完成签到 ,获得积分10
9秒前
定海神针铁完成签到,获得积分10
10秒前
萧雨墨发布了新的文献求助10
11秒前
大模型的应助被开朗天问采纳,获得10
12秒前
带派不老铁完成签到 ,获得积分10
13秒前
坚强血茗完成签到 ,获得积分10
18秒前
19秒前
22秒前
suyongye完成签到,获得积分10
23秒前
熊猫四海完成签到 ,获得积分10
33秒前
科研通AI6.4的应助被YCLING采纳,获得10
36秒前
玖嬴完成签到,获得积分10
39秒前
Owen的应助被北极幸运星采纳,获得20
40秒前
可靠之玉发布了新的文献求助30
42秒前
helloWorld完成签到,获得积分10
44秒前
45秒前
kiki发布了新的文献求助10
49秒前
50秒前
萧雨墨发布了新的文献求助10
52秒前
53秒前
57秒前
pang完成签到,获得积分10
1分钟前
1分钟前
努力学习中完成签到,获得积分10
1分钟前
余香的应助被萧雨墨采纳,获得10
1分钟前
1分钟前
YCLING发布了新的文献求助10
1分钟前
1分钟前
infinity完成签到 ,获得积分10
1分钟前
小蘑菇的应助被从容问柳采纳,获得100
1分钟前
ubless607给成博的求助进行了留言
1分钟前
666完成签到 ,获得积分10
1分钟前
田様的应助被sissiarno采纳,获得10
1分钟前
共享精神的应助被sissiarno采纳,获得10
1分钟前
余香的应助被sissiarno采纳,获得10
1分钟前
1分钟前
嘻嘻哈哈的应助被sissiarno采纳,获得10
1分钟前
Nole完成签到,获得积分0
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190049
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851842
捐赠科研通 7788131
什么是DOI,文献DOI怎么找? 3436227
关于科研通互助平台的介绍 2559910
邀请新用户注册赠送积分活动 2482768